A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Calliditas Therapeutics Suisse SA
- Target Recruit Count
- 55
- Registration Number
- NCT05323656
- Locations
- 🇫🇷
Ramsay Health Clinic Belharra, Bayonne, France
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇬🇧The Royal Marsden Hospital - London, London, England, United Kingdom
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Calliditas Therapeutics Suisse SA
- Target Recruit Count
- 76
- Registration Number
- NCT05014672
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇦🇹Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, Oberösterreich, Austria
🇵🇱ID Clinic, Myslowice, Poland
© Copyright 2024. All Rights Reserved by MedPath